Neuroscience Research Institute
Clinical Trials
Vivistim Registry for Paired VNS Therapy (GRASP)
This study is currently enrolling.
The purpose of this particular registry is to collect information about patients who have had a stroke and still have upper-limb difficulties. This registry includes information before and after device implant, and includes op ...
“A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients with Motor Fluctuations due to Parkinson’s Disease”
This study is currently enrolling.
The purpose of this clinical research study is to look at an investigational study drug called lenrispodun. The study will investigate if lenrispodun can help to increase the time of good control of movement symptoms, that is, ...
A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks.
You, or you and the individual you care for, are being asked to take part in a research study because you have seizures associated with developmental and epileptic encephalopathy (DEE) and you have completed study LP352-201. L ...
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 deficiency disorder followed by an Open-Label Extension.
The purpose of this informed consent form is to collect data about the non-paid caregiver of a subject that is participating in ZX008-2103 study. You, as the non-paid caregiver, are being asked to complete the EQ-5D-5L Quality ...
An Open-Label, Single-Dose, Pharmacokinetics Study of VALTOCO with Open-Label Safety Period in Pediatric Subjects with Epilepsy
This is a research study to evaluate the pharmacokinetics (PK), safety and tolerability after a single intranasal dose of VALTOCO (diazepam nasal spray), followed by a long-term safety period, where VALTOCO will be used “as nee ...